Medical Condition News

RSS

Discovery suggests how toxin-filtering cells go awry

Researchers from Children's Hospital Boston and Brigham and Women's Hospital have identified an important genetic cause of a devastating kidney disease that is the second leading cause of kidney failure in children, according to The NephCure Foundation.

22 Dec 2009

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].

22 Dec 2009

Heart transplant patients face increased risk for skin cancers

Many heart transplant patients develop multiple skin cancers, with increased risk for some skin cancers among patients with other cancers and with increasing age, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Dec 2009

Depressed patients are unable to sustain positive emotions, says study

A new study at the University of Wisconsin-Madison suggests that depressed patients are unable to sustain activity in brain areas related to positive emotion.

22 Dec 2009

Smoking, weight and skin cancer are associated with skin aging

Smoking, being heavier, not using sunscreen and having had skin cancer appear to be associated with sun damage and aging of skin on the face, according to report based on a study of twins in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Dec 2009

SafeMinds disappointed with CDC's report on autism spectrum disorders

A study released Friday by the Centers for Disease Control (CDC) reported that autism prevalence has increased a staggering 57% from the 1994 rate of 1 in 150 to 1 in 110 for children born in 1996. SafeMinds is extremely dissatisfied with CDC's lack of commitment to researching environmental causes and the timing of their announcement.

22 Dec 2009

LEO Pharma announces positive results for two Phase III AK clinical trials

LEO Pharma today announced positive results for the company’s two Phase III actinic (solar) keratosis (AK) clinical trials using PEP005 (ingenol mebutate) Gel for the treatment of lesions on head treatment areas, which include the face and scalp.

22 Dec 2009

BUSM researchers discover new gene therapy for treating emphysema patients

Researchers from Boston University School of Medicine (BUSM) have discovered a new gene therapy that may prevent the progression of emphysema. The study, which appears on-line in the Journal of Clinical Investigation, describes a method to express therapeutic genes in lung tissue for a lifetime after only a single treatment.

22 Dec 2009

While mortality from diabetes declines in Canada, the income-related mortality gap increases

While mortality from diabetes has declined in Canada, the income-related mortality gap is increasing, with lower income groups faring worse than higher income groups, according to a new studyhttp://www.cmaj.ca/embargo/cmaj090495.pdf in CMAJ ( Canadian Medical Association Journal) www.cmaj.ca.

22 Dec 2009

AAPM dispels common myths about CT scans

A panel of experts at the American Association of Physicists in Medicine (AAPM) has issued a statement calling for an open discussion of the facts about radiation hazards from computed tomography (CT) scanning in light of recent public concerns and news reports about radiation dose.

22 Dec 2009

CyberKnife Robotic Radiosurgery System brings new hope to patients with inoperable tumors

The CyberKnife Institute at Mercy Hospital, Miami’s first hospital-based CyberKnife® Robotic Radiosurgery System, will bring new hope to patients with inoperable or surgically complex tumors when it opens its doors January of 2010.

22 Dec 2009

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Bryan Oncor reports the results of a Phase I trial of its targeted radiopharmaceutical therapy using Re-88 P2045, a radiolabeled synthetic peptide, for the treatment of advanced lung cancer.

21 Dec 2009

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

NeoStem, Inc. (NYSE Amex: NBS), which is a leading provider of pre-disease adult stem cell collection, processing and long-term storage services, and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that five posters and two oral presentations at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans in early December demonstrated the basic cellular mechanisms of very small embryonic-like stem cells.

21 Dec 2009

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

CPEX Pharmaceuticals, Inc. today announced that the ongoing Phase 2a clinical trial of Nasulin™, the Company’s intranasal insulin candidate, has now completed enrollment. The study was initiated in February of this year and randomized 94 subjects. Results are expected at the end of the first quarter or beginning of the second quarter of 2010.

21 Dec 2009

Investigation of IDH1 gene mutations in brain cancer receives new funds

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2’s funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios’s ongoing research into the development of new IDH1 therapeutics and diagnostics.

21 Dec 2009

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.

21 Dec 2009

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

21 Dec 2009

Medical Condition News

Discovery suggests how toxin-filtering cells go awry

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

Heart transplant patients face increased risk for skin cancers

Depressed patients are unable to sustain positive emotions, says study

Smoking, weight and skin cancer are associated with skin aging

SafeMinds disappointed with CDC's report on autism spectrum disorders

LEO Pharma announces positive results for two Phase III AK clinical trials

BUSM researchers discover new gene therapy for treating emphysema patients

While mortality from diabetes declines in Canada, the income-related mortality gap increases

AAPM dispels common myths about CT scans

CyberKnife Robotic Radiosurgery System brings new hope to patients with inoperable tumors

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

Investigation of IDH1 gene mutations in brain cancer receives new funds

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News